A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 595-604

  Chiorean, E Gabriela ^a,g   Sweeney, Christopher ^b   Youssoufian, Hagop ^c,d   Qin, Amy ^c   Dontabhaktuni, Aruna ^c   Loizos, Nick ^c   Nippgen, Johannes ^c,e   Amato, Robert ^f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Clinical Research   (United States)

^e GLYCOTOPE GMBH   (Germany)

^f UNIVERSITY OF TEXAS   (United States)

^g INDIANA UNIVERSITY   (United States)

Author keywords

IMC 3G3; Olaratumab; Phase I; Platelet derived growth factor receptor; Solid tumors

Indexed keywords

IMC 3G 3; OLARATUMAB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INFUSION RELATED REACTION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR XENOGRAFT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME;

EID: 84896053860     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2389-9     Document Type: Article

References (43)

1. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316 (Pubitemid 29473317)
2. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B (1993) Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotrans-planted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90:393-397 (Pubitemid 23028868)
3. Ostman A (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15:275-286
4. Dong J, Grunstein J, Tejada M et al (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23:2800-2810 (Pubitemid 39013552)
5. Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD (2007) PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol 104:524-528 (Pubitemid 46240237)
6. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550-4553
7. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD (2006) Autocrine activation of PDG-FRalpha promotes the progression of ovarian cancer. Oncogene 25:2060-2069
8. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP (2007) Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 6:1932-1941 (Pubitemid 47052483)
9. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 7:R788-R795
10. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP (1999) Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155:1271-1279 (Pubitemid 29488934)
11. Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M, Oberg K (1993) Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550-4554 (Pubitemid 23304378)
12. Sulzbacher I, Birner P, Träxler M, Marberger M, Haitel A (2003) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120:107-112 (Pubitemid 37046377)
13. Alentorn A, Marie Y, Carpentier C et al (2012) Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. Neuro Oncol 14:1393-1403
14. Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura EB (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72:2501-2511
15. Ehnman M, Missiaglia E, Folestad E et al (2013) Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 73:2139-2149
16. LaRochelle WJ, Jensen RA, Heidaran MA, May-Siroff M, Wang LM, Aaronson SA, Pierce JH (1993) Inhibition of platelet-derived growth factor autocrine growth stimulation by a monoclonal antibody to the human alpha platelet-derived growth factor receptor. Cell Growth Differ 4:547-553
17. Lokker NA, O'Hare JP, Barsoumian A, Tomlinson JE, Ramakrishnan V, Fretto LJ, Giese NA (1997) Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies. J Biol Chem 272:33037-33044 (Pubitemid 28023644)
18. Loizos N, Xu Y, Huber J et al (2005) Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 4:369-379 (Pubitemid 40443922)
19. Levitzki A (2004) PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 15:229-235
20. Dai Y (2010) Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opin Ther Pat 20:885-897
21. Dolloff NG, Russell MR, Loizos N, Fatatis A (2007) Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res 67:555-562 (Pubitemid 46192192)
22. Russell MR, Liu Q, Fatatis A (2010) Targeting the alpha receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 16:5002-5010
23. Gerber DE, Gupta P, Dellinger MT et al (2012) Stromal platelet derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts. Mol Cancer Ther 11:2473-2482
24. Chiorean EG, Sweeney C, Youssoufian H, Fox F, Katz T, Rowinsky E, Amato R (2008) Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies [abstract 511 and poster]. Presented at EORTC-NCI-AACR Annual Meeting 2008, Geneva, Switzerland, Oct 21-24
25. Jayson GC, Parker GJ, Mullamitha S et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973-981 (Pubitemid 46202317)
26. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 (Pubitemid 32267972)
27. National Cancer Institute (2006) Cancer therapy evaluation program common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed 05 Dec 2013
28. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
29. Rodt SA, Ahlén K, Berg A, Rubin K, Reed RK (1996) A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 495(Pt 1):193-200 (Pubitemid 26288464)
30. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480 (Pubitemid 34879334)
31. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35 (Pubitemid 46630490)
32. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G (2005) Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11:5223-5232 (Pubitemid 41003710)
33. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19:265-272 (Pubitemid 32063505)
34. Rowinsky EK (2000) The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 60(Suppl 1):1-14
35. Fudge K, Bostwick DG, Stearns ME (1996) Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 29:282-286 (Pubitemid 26372600)
36. Russell MR, Jamieson WL, Dolloff NG, Fatatis A (2009) The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 28:412-421
37. Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A (2010) The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Cancer Res 70:4195-4203
38. Knösel T, Chen Y, Altendorf-Hofmann A, Danielczok C, Freesmeyer M, Settmacher U, Wurst C, Schulz S, Yang LL, Petersen I (2012) High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. J Cancer Res Clin Oncol 138:397-403
39. Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET (2006) Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 84:42-48 (Pubitemid 44973686)
40. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145
41. Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359
42. Wozniak A, Rutkowski P, Piskorz A et al (2012) Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 23:353-360
43. ClinicalTrials.gov [web site]. http://clinicaltrials.gov. Accessed 05 Dec 2013